Taken together, these results demonstrate that the JAK2/BECN1 complex plays an important role in CRC chemotherapy resistance and that p-BECN1 (Y333) is a potential predictor of CRC outcome and chemotherapy drug resistance. Here, JAK2 is linked to colorectal carcinoma.